Celator® Pharmaceuticals Announces Business Update and Fourth Quarter and Full Year 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
NDA, MAA Remain Key Focal Points for Celator Pharma (CPXX) Moving Forward; Roth Affirms at 'Buy'
March 21, 2016 11:31 AM EDTRoth Capital affirms Celator Pharmaceuticals (Nasdaq: CPXX) with a Buy rating and $22 price target after the company announced FY15 results earlier.
Analyst Joseph Pantginis noted that Celator posted FY15 EPS of ($0.57), which compares with the firm's ($0.56) estimate.
Pantginis also commented: With historic data in hand and a significantly de-risked program, in... More
Celator Pharmaceuticals (CPXX) Misses Q4 EPS by 1c
March 21, 2016 8:21 AM EDTCelator Pharmaceuticals (NASDAQ: CPXX) reported Q4 EPS of ($0.13), $0.01 worse than the analyst estimate of ($0.12).
The following are expected milestones for VYXEOS:
3Q 2016 New Drug Application (NDA) submission1Q 2017 Marketing Authorization Application (MAA) submissionMid-2017 Prescription Drug User Fee Act (PDUFA)... More